vs
PEOPLES BANCORP INC（PEBO）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是PEOPLES BANCORP INC的1.1倍（$127.1M vs $118.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 3.7%）
该公司是总部位于美国明尼苏达州明尼阿波利斯、在特拉华州注册的美国跨国银行机构。截至2025年，它是美国第五大银行，同时也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的金融机构。它主营银行、投资、抵押贷款等相关金融业务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
PEBO vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.1倍
$118.7M
两年增速更快
ZLAB
近两年复合增速
3.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $118.7M | $127.1M |
| 净利润 | $29.0M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 24.4% | — |
| 营收同比 | — | 17.1% |
| 净利润同比 | -8.7% | — |
| 每股收益（稀释后） | $0.81 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PEBOZLAB
| Q1 26 | $118.7M | — | ||
| Q4 25 | $117.3M | $127.1M | ||
| Q3 25 | $115.2M | $115.4M | ||
| Q2 25 | $114.5M | $109.1M | ||
| Q1 25 | $112.4M | $105.7M | ||
| Q4 24 | $111.6M | $108.5M | ||
| Q3 24 | $113.7M | $101.8M | ||
| Q2 24 | $110.3M | $100.1M |
净利润PEBOZLAB
| Q1 26 | $29.0M | — | ||
| Q4 25 | $31.8M | — | ||
| Q3 25 | $29.5M | $-36.0M | ||
| Q2 25 | $21.2M | $-40.7M | ||
| Q1 25 | $24.3M | $-48.4M | ||
| Q4 24 | $26.9M | — | ||
| Q3 24 | $31.7M | $-41.7M | ||
| Q2 24 | $29.0M | $-80.3M |
毛利率PEBOZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率PEBOZLAB
| Q1 26 | — | — | ||
| Q4 25 | 32.4% | -54.6% | ||
| Q3 25 | 33.0% | -42.3% | ||
| Q2 25 | 24.0% | -50.3% | ||
| Q1 25 | 27.9% | -53.3% | ||
| Q4 24 | 31.2% | -62.6% | ||
| Q3 24 | 36.0% | -66.6% | ||
| Q2 24 | 32.5% | -76.0% |
净利率PEBOZLAB
| Q1 26 | 24.4% | — | ||
| Q4 25 | 27.1% | — | ||
| Q3 25 | 25.6% | -31.2% | ||
| Q2 25 | 18.5% | -37.3% | ||
| Q1 25 | 21.7% | -45.8% | ||
| Q4 24 | 24.1% | — | ||
| Q3 24 | 27.9% | -40.9% | ||
| Q2 24 | 26.3% | -80.2% |
每股收益（稀释后）PEBOZLAB
| Q1 26 | $0.81 | — | ||
| Q4 25 | $0.89 | $-0.05 | ||
| Q3 25 | $0.83 | $-0.03 | ||
| Q2 25 | $0.59 | $-0.04 | ||
| Q1 25 | $0.68 | $-0.04 | ||
| Q4 24 | $0.76 | $-0.09 | ||
| Q3 24 | $0.89 | $-0.04 | ||
| Q2 24 | $0.82 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.9M | $689.6M |
| 总债务越低越好 | $691.3M | — |
| 股东权益账面价值 | $1.2B | $715.5M |
| 总资产 | $9.6B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.57× | — |
8季度趋势，按日历期对齐
现金及短期投资PEBOZLAB
| Q1 26 | $82.9M | — | ||
| Q4 25 | $189.0M | $689.6M | ||
| Q3 25 | $190.2M | $717.2M | ||
| Q2 25 | $186.1M | $732.2M | ||
| Q1 25 | $187.0M | $757.3M | ||
| Q4 24 | $217.7M | $779.7M | ||
| Q3 24 | $283.7M | $616.1M | ||
| Q2 24 | $235.9M | $630.0M |
总债务PEBOZLAB
| Q1 26 | $691.3M | — | ||
| Q4 25 | $204.1M | — | ||
| Q3 25 | $227.3M | — | ||
| Q2 25 | $232.4M | — | ||
| Q1 25 | $237.0M | — | ||
| Q4 24 | $238.1M | — | ||
| Q3 24 | $236.8M | — | ||
| Q2 24 | $234.3M | — |
股东权益PEBOZLAB
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $715.5M | ||
| Q3 25 | $1.2B | $759.9M | ||
| Q2 25 | $1.2B | $791.7M | ||
| Q1 25 | $1.1B | $810.8M | ||
| Q4 24 | $1.1B | $840.9M | ||
| Q3 24 | $1.1B | $667.7M | ||
| Q2 24 | $1.1B | $704.2M |
总资产PEBOZLAB
| Q1 26 | $9.6B | — | ||
| Q4 25 | $9.6B | $1.2B | ||
| Q3 25 | $9.6B | $1.2B | ||
| Q2 25 | $9.5B | $1.2B | ||
| Q1 25 | $9.2B | $1.2B | ||
| Q4 24 | $9.3B | $1.2B | ||
| Q3 24 | $9.1B | $985.3M | ||
| Q2 24 | $9.2B | $987.4M |
负债/权益比PEBOZLAB
| Q1 26 | 0.57× | — | ||
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.21× | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 0.21× | — | ||
| Q2 24 | 0.22× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流PEBOZLAB
| Q1 26 | — | — | ||
| Q4 25 | $134.7M | $-26.0M | ||
| Q3 25 | $14.4M | $-32.0M | ||
| Q2 25 | $50.7M | $-31.0M | ||
| Q1 25 | $34.3M | $-61.7M | ||
| Q4 24 | $143.2M | $-55.8M | ||
| Q3 24 | $34.1M | $-26.8M | ||
| Q2 24 | $32.1M | $-42.2M |
自由现金流PEBOZLAB
| Q1 26 | — | — | ||
| Q4 25 | $128.7M | $-26.7M | ||
| Q3 25 | $12.7M | $-35.0M | ||
| Q2 25 | $49.2M | $-33.9M | ||
| Q1 25 | $31.5M | $-63.2M | ||
| Q4 24 | $136.4M | $-58.4M | ||
| Q3 24 | $33.2M | $-28.2M | ||
| Q2 24 | $30.2M | $-42.9M |
自由现金流率PEBOZLAB
| Q1 26 | — | — | ||
| Q4 25 | 109.7% | -21.0% | ||
| Q3 25 | 11.0% | -30.4% | ||
| Q2 25 | 43.0% | -31.1% | ||
| Q1 25 | 28.1% | -59.9% | ||
| Q4 24 | 122.2% | -53.8% | ||
| Q3 24 | 29.2% | -27.7% | ||
| Q2 24 | 27.4% | -42.9% |
资本支出强度PEBOZLAB
| Q1 26 | — | — | ||
| Q4 25 | 5.1% | 0.5% | ||
| Q3 25 | 1.5% | 2.6% | ||
| Q2 25 | 1.3% | 2.6% | ||
| Q1 25 | 2.4% | 1.5% | ||
| Q4 24 | 6.1% | 2.4% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | 1.7% | 0.7% |
现金转化率PEBOZLAB
| Q1 26 | — | — | ||
| Q4 25 | 4.24× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.41× | — | ||
| Q4 24 | 5.32× | — | ||
| Q3 24 | 1.08× | — | ||
| Q2 24 | 1.11× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PEBO
| Net Interest Income | $90.4M | 76% |
| Noninterest Income | $28.3M | 24% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
